Objectives
The primary objective of the TRITICC trial is to examine the efficacy of a combination therapy of FTD/TPI and Irinotecan in patients with advanced, non resectable or metastatic BTC after failure to respond to a previous gemcitabine based treatment. Secondary objectives are to determine the efficacy and safety of the treatment concept, health-related quality of life (HR-QoL) and translational investigation.